Pulmatrix (NASDAQ:PULM) Receives New Coverage from Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM) in a research note issued to investors on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Pulmatrix Price Performance

PULM stock opened at $2.14 on Tuesday. Pulmatrix has a 52 week low of $1.55 and a 52 week high of $2.75. The company has a fifty day simple moving average of $2.10 and a two-hundred day simple moving average of $1.99. The firm has a market capitalization of $7.82 million, a P/E ratio of -0.89 and a beta of 0.99.

Pulmatrix (NASDAQ:PULM) last released its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.87) EPS for the quarter. Pulmatrix had a negative net margin of 95.18% and a negative return on equity of 46.86%. The business had revenue of $1.55 million for the quarter.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.